Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Abiomed Inc (NQ: ABMD )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abiomed Inc

< Previous 1 2 Next >
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
From Abiomed, Inc.
Via Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
First Patients in the World Treated with Impella RP Flex with SmartAssist
From Abiomed, Inc.
Via Business Wire
ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
From Kahn Swick & Foti, LLC
Via Business Wire
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
Exposures US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
From Kahn Swick & Foti, LLC
Via Business Wire
Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR
Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to 
Via Spotlight Growth
Exposures Product Safety
ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
From Abiomed, Inc.
Via Business Wire
Johnson & Johnson to Acquire Abiomed
From Johnson & Johnson
Via Business Wire
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
From Abiomed, Inc.
Via Business Wire
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
From Abiomed, Inc.
Via Business Wire
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
From Abiomed, Inc.
Via Business Wire
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
From Abiomed, Inc.
Via Business Wire
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
From Abiomed, Inc.
Via Business Wire
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
From Abiomed, Inc.
Via Business Wire
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
From Abiomed, Inc.
Via Business Wire
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
From Abiomed, Inc.
Via Business Wire
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
From Abiomed, Inc.
Via Business Wire
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
From Abiomed, Inc.
Via Business Wire
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
From Abiomed, Inc.
Via Business Wire
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
From Abiomed
Via Business Wire
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
From Abiomed, Inc.
Via Business Wire
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
From Abiomed, Inc.
Via Business Wire
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
From Abiomed, Inc.
Via Business Wire
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
From Abiomed
Via Business Wire
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
From Abiomed, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.